IP Library › Granted Patent US 12,280,196
Granted Patent B2
US 12,280,196 · App. 17/823,120 · Granted Apr 22, 2025

Methods of using polymers

Inventors: Phillip P. Chan (Cherry Hill, NJ); Vincent J. Capponi (Lawrenceville, NJ); Thomas D. Golobish (Princeton, NJ); Humayra Begum Ali (Princeton, NJ)
Assignee: CytoSorbents, Inc.
A61M1/3679A61K9/16A61K31/765B01J20/261B01J20/28069B01J20/28078C08F299/00C08J9/26A61M2202/0057A61M2202/0405A61M2202/0413A61M2202/0415A61M2202/0423A61M2202/0464A61M2202/0466A61M2202/049A61M2202/0492A61M2202/0496A61M2202/20A61M2202/203A61M2202/206C08J2201/0444C08J2207/10C08J2353/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,280,196
App. No.
17/823,120
Granted
Apr 22, 2025
Kind
B2
Abstract

Provided herein are materials and methods of reducing contamination in a biological substance or treating contamination in a subject by one or more toxins comprising contacting the biological substance with an effective amount of a sorbent capable of sorbing the toxin, wherein the sorbent comprises a plurality of pores ranging from 50 Å to 40,000 Å with a pore volume of 0.5 cc/g to 5.0 cc/g and a size of 0.05 mm to 2 cm and sorbing the toxin. Also provided are kits to reduce contamination by one or more toxins in a biological substance comprising a sorbent capable of sorbing a toxin, wherein the sorbent comprises a plurality of pores ranging from 50 Å to 40,000 Å with a pore volume of 0.5 cc/g to 5.0 cc/g and a size of 0.05 mm to 2 cm and a vessel to store said sorbent when not in use together with packaging for same.

Claims (26)

1. A method of reducing contamination by at least two toxins in a biological substance, said method comprising:

a. contacting the biological substance with an effective amount of a sorbent capable of sorbing the toxins, wherein the sorbent comprises a plurality of pores ranging from 50 Å to 40,000 Å with a pore volume of 0.5 cc/g to 5.0 cc/g and a size of 0.05 mm to 2 cm, wherein the sorbent comprises a coated polymer comprising at least one crosslinking agent and wherein said toxins comprise a first toxin having a molecular weight of less than or equal to 50,000 Daltons and a second toxin having a molecular weight greater than 50,000 Daltons; and

b. sorbing the toxins.

2. The method of claim 1 , wherein the sorbent is biocompatible.

3. The method of claim 1 , wherein the polymer is a microporous polymeric sorbent.

4. The method of claim 1 , wherein the sorbing occurs in vivo.

5. The method of claim 1 , wherein the sorbing occurs ex vivo.

6. The method of claim 1 , wherein the biological substance comprises cells or physiologic fluids such as saliva, nasopharyngeal fluid, blood, plasma, serum, saliva, gastrointestinal fluid, bile, cerebrospinal fluid, pericardial, vaginal fluid, seminal fluid, prostatic fluid, peritoneal fluid, pleural fluid, urine, synovial fluid, interstitial fluid, intracellular fluid, extracellular fluid, lymph, mucus, or vitreous humor.

7. The method of claim 1 , wherein the method further comprises the steps of producing or purifying a blood product or biologic.

8. The method of claim 7 , wherein the blood product comprises whole blood, packed red blood cells, platelets, plasma, cryoprecipitate, white blood cells, pluripotent stem cells, T-cells, B-cells, or other cells of myloid or lymphoid origin and their progenitors.

9. The method of claim 1 , wherein contamination by the toxins is systemic or localized.

10. The method of claim 1 , wherein the sorbent is introduced through a body cavity.

11. The method of claim 10 , wherein the sorbent is introduced orally, vaginally, rectally or nasally, through a feeding tube or topically.

12. The method of claim 1 , wherein the sorbent is introduced by hemoperfusion.

13. The method of claim 1 , wherein the sorbent is used for extracorporeal treatment of a biological substance comprising saliva, blood, plasma, serum, gastrointestinal fluid, cerebrospinal fluid, vaginal fluid, peritoneal fluid, pleural fluid, urine, synovial fluid, lymph, alveolar mucus or vitreous humor.

14. The method of claim 1 , wherein the sorbent has a pore structure such that the total pore volume of pore size in the range of 50 Å to 40,000 Å is greater than 0.5 cc/g to 5.0 cc/g dry sorbent; wherein the ratio of pore volume between 50 Å to 40,000 Å (pore diameter) to pore volume between 100 Å to 1,000 Å (pore diameter) of the sorbent is smaller than 3:1.

15. The method of claim 1 , wherein the sorbent has a pore structure such that the total pore volume of pore size in the range of 50 Å to 40,000 Å is greater than 0.5 cc/g to 5.0 cc/g dry sorbent; wherein the ratio of pore volume between 50 Å to 40,000 Å (pore diameter) to pore volume between 1,000 Å to 10,000 Å (pore diameter) of the sorbent is smaller than 2:1.

16. The method of claim 1 , wherein the sorbent has a pore structure such that the total pore volume of pore size in the range of 50 Å to 40,000 Å is greater than 0.5 cc/g to 5.0 cc/g dry sorbent; wherein the ratio of pore volume between 50 Å to 40,000 Å (pore diameter) to pore volume between 10,000 Å to 40,000 Å (pore diameter) of the sorbent is smaller than 3:1.

17. The method of claim 1 , wherein the sorbent comprises a plurality of pores comprising at least one crosslinking agent, at least one monomer, and at least one dispersing agent.

18. The method of claim 17 , wherein the dispersing agent is one or more of hydroxyethyl cellulose, hydroxypropyl cellulose, poly (hydroxyethyl methacrylate), poly (hydroxyethyl acrylate), poly (hydroxypropyl methacrylate), poly (hydroxypropyl acrylate), poly (dimethylaminoethyl methacrylate), poly (dimethylaminoethyl acrylate), poly (diethylaminoethyl methacrylate), poly (diethylaminoethyl acrylate), poly (vinyl alcohol), poly (N-vinylpyrrolidinone), salts of poly (methacrylic acid), or salts of poly (acrylic acid).

19. The method of claim 17 , wherein the crosslinking agent is one or more of divinylbenzene, trivinylbenzene, divinylnaphthalene, trivinylcyclohexane, divinylsulfone, trimethylolpropane trimethacrylate, trimethylolpropane dimethacrylate, trimethylolpropane triacrylate, trimethylolpropane diacrylate, pentaerythrital dimethacrylates, pentaerythrital trimethacrylates, pentaerythrital tetramethacrylates, pentaerythritol diacrylates, pentaerythritol triacrylates, pentaerythritol tetraacrylates, dipentaerythritol dimethacrylates, dipentaerythritol trimethacrylates, dipentaerythritol tetramethacrylates, dipentaerythritol diacrylates, dipentaerythritol triacrylates, dipentaerythritol tetraacrylates, or divinylformamide.

20. The method of claim 17 , wherein monomer is one or more of divinylbenzene and ethylvinylbezene, styrene, ethylstyrene, acrylonitrile, butyl methacrylate, octyl methacrylate, butyl acrylate, octyl acrylate, cetyl methacrylate, cetyl acrylate, ethyl methacrylate, ethyl acrylate, vinyltoluene, vinylnaphthalene, vinylbenzyl alcohol, vinylformamide, methyl methacrylate, methyl acrylate, trivinylbenzene, divinylnaphthalene, trivinylcyclohexane, divinylsulfone, trimethylolpropane trimethacrylate, trimethylolpropane dimethacrylate, trimethylolpropane triacrylate, trimethylolpropane diacrylate, pentaerythritol dimethacrylate, pentaerythritol trimethacrylate, pentaerythritol tetramethacrylate, pentaerythritol diacrylate, pentaerythritol triacrylate, pentaerythritol tetraacrylate, dipentaerythritol dimethacrylate, dipentaerythritol trimethacrylate, dipentaerythritol tetramethacrylate, dipentaerythritol diacrylate, dipentaerythritol triacrylate, dipentaerythritol tetraacrylate, divinylformamide and mixtures thereof.

21. The method of claim 1 , wherein the sorbent is a mixture of sorbents with two or more different pore sizes.

22. The method of claim 1 , wherein the sorbent is formulated as a powder, tablet, capsule, solution, gel tab, dispersion, slurry, suppository, or suspension.

23. The method of claim 1 , wherein the sorbent is admixed with food, fluid, or any combination thereof.

24. The method of claim 1 , wherein the toxins comprise one or both of Clostridium difficile Toxin A and Clostridium difficile Toxin B.

Assignments (1)
SECURITY INTEREST Recorded Jun 28, 2024
From: CYTOSORBENTS CORPORATION
To: AVENUE CAPITAL MANAGEMENT II, L.P.
Reel/Frame 067964/0382 →
Continuity (4)
Continuation 15497640 · Apr 26, 2017
Continuation 14410901
Provisional Application 61666626 · Jun 29, 2012
Related Publication 20230166019A1 · Jun 1, 2023
References Cited (45)
US 5633290A · Frechet et al. · 1997 [cited by applicant]
US 5726118A · Ivey et al. · 1998 [cited by applicant]
US 6890523B2 · Kurtz et al. · 2005 [cited by applicant]
US 7678369B2 · Kurtz et al. · 2010 [cited by applicant]
US 11602585B2 · Chan · 2023 [cited by examiner]
US 20030027879A1 · Davankov et al. · 2003 [cited by applicant]
US 20060099169A1 · Charmot et al. · 2006 [cited by applicant]
US 20080119576A1 · Young et al. · 2008 [cited by applicant]
US 20080213523A1 · Fujimoto et al. · 2008 [cited by applicant]
US 20100172861A1 · Kurtz et al. · 2010 [cited by applicant]
US 20110070424A1 · Young et al. · 2011 [cited by applicant]
US 20130011824A1 · Chan et al. · 2013 [cited by applicant]
CN 101307149B · 2011 [cited by applicant]
JP 2002035118A · 2002 [cited by applicant]
JP 2018027220A · 2018 [cited by applicant]
WO WO2000043120A1 · 2000 [cited by applicant]
WO WO2005123952A2 · 2005 [cited by applicant]
WO WO2006086428A2 · 2006 [cited by applicant]
WO WO2009158027A1 · 2009 [cited by applicant]
WO WO2011070363A1 · 2011 [cited by applicant]
WO WO2011100354A1 · 2011 [cited by applicant]
WO WO2011123767A1 · 2011 [cited by examiner]
WO WO2012033522A1 · 2012 [cited by applicant]
WO WO2012094565A1 · 2012 [cited by applicant]
WO WO2013025483A2 · 2013 [cited by applicant]
WO WO2014005039A2 · 2014 [cited by applicant]
McFarland, L.V., Emerging therapies for Clostridium difficile infections, Expert Opin. Emerg. Drugs, 16 (2011) pp. 425-439. (Year: 2011). [cited by examiner]
Taniguchi et al. “Novel adsorbent of circulating bacterial toxins and cytokines: The effect of direct hemoperfusion with CTR column for the treatment of experimental endotoxemia”, Grit Care Med, 34(3), 2006, pp. 800-806. [cited by applicant]
Anderson et al., “The Human Plasma Proteome. History, Character, and Diagnostic Prospects”, Molecular & Cellular Proteomics, American Society For Biochemistry And Molecular Biology, Jan. 1, 2002, 845-867. [cited by applicant]
“CytoSorb is a Novel Application of Tried and True Technology”, Chemistfrog's Instablog, Seeking Alpha, Chemistfrog 11, http://seekingalgha.com/instablog/399559-chemistfrog/78833-cytosorb-is-a-novel-application-of-tried… [cited by applicant]
Banno et al., “Biochemical Characterization and Biologic Actions of Two Toxins (D-1 and D-2) from Clostridium Difficile”, Clinical Infectious Disease, 1984, 6 (Supp. 1), S11-S20. [cited by applicant]
Banno et al., “Two Toxins (D-1 and D-2) of Clostridium Difficile Causing Antibiotic-Associated Colitis: Purification and Some Characterization”, Biochem. Int., 1981, 2(6), 629-635. [cited by applicant]
Gerding et al., “Treatment of Clostridium Difficile Infection”, Clinical Infectious Diseases, 2008, 46(Supp 1), S32-S42. [cited by applicant]
Gill et al., “Foodborne Illnesses”, Current Treatment Options In Gastroenterology, 2001, 4, 23-38. [cited by applicant]
Gouliouris et al., “Prevention and Treatment of Clostridium Difficile Infection”, Clinical Medicine, 2011, 11(1), 75-79. [cited by applicant]
Johal et al., “Differential Effects of Varying Concentrations of Clostridium difficile Toxin A on Epithelial Barrier Function and Expression of Cytokines”, The Journal of Infectious Disease, 2004, 189, 2110-2119. [cited by applicant]
Kopic et al., “Toxin Mediated Diarrhea in the 21st Century: The Pathophysiology of Intestinal Ion Transport in the Course of Etec, V. Cholerae and Rotavirus Infection”, Toxins, 2010, 2, 2132-2157. [cited by applicant]
Krivan et al., “Purification of Clostridium Difficile Toxin A By Affinity Chromatography On Immobilized Thyroglobulin”, Infection and Immunity, 1987, 55(8), 1873-1877. [cited by applicant]
Lyerly et al., “Characterization of Toxins A and B of Clostridium Difficile with Monoclonal Antibodies”, Infection and Immunity, 1986, 70-76. [cited by applicant]
Lyerly et al., “Clostridium Difficile: Its Disease and Toxins”, Clinical Microbiology Reviews, 1988, 1-18. [cited by applicant]
Wagner, Jr., “Baterial Food Poisoning”, Texas Agricultural Extension Service, www.ecosafeusa.com, 1989, 6 pages. [cited by applicant]
Modern Physician, vol. 31, No. 5, 2011, pp. 574-577. [cited by applicant]
Office Action issued in Japanese Patent Application No. 2015-520580, dated Oct. 17, 2017. [cited by applicant]
European Patent Application No. 20158282.2; Extended Search Report; dated May 11, 2020; 11 pages. [cited by applicant]
McFarland, “Emerging therapies for Clostridium difficile infections”, Expert Opinion on Emerging Drugs, 16:3, 2011, pp. 425-439. [cited by applicant]